



DVT

Meets outpatient criteria?

No

Yes

Admit

Significant extremity swelling?

Send home on apixaban (Eliquis®)
10 mg PO BID x 7 days then 5 mg PO BID
Follow with PCP in 1 week

Yes

No

• Consult IR or Vascular surgery for direct management
• GFR greater than or equal to 15: Start enoxaparin (Lovenox®)
• Renally adjust if GFR less than 30
• GFR less than 15: Start heparin gtt

Catheter Associated:

Yes

No

Criteria for Outpatient Management

- Low bleeding risk
 - Platelets greater than 50
 - Normal INR
 - Normal LFTs
 - No recent bleeding
- No significant extremity swelling
- Normal vital signs
- No other reason for hospitalization
- GFR greater than 25

Is catheter functioning?

No

Yes

- Cathflo
- Start anticoagulation if function regained
- If no effect from cathflo AND line is permanent/necessary consult IR for intervention
• GFR greater than or equal to 15: Start enoxaparin (Lovenox®)
• Renally adjust if GFR less than 30
• GFR less than 15: Start heparin gtt
- If no effect from cathflo AND line is NO longer required, remove line and start anticoagulation (options to the right)

• Recent significant bleeding or contraindications to anticoagulation → IVC filter
• GFR less than 15: heparin gtt followed by warfarin with goal INR 2-3
• GFR 15-25: Enoxaparin (renally adjust) bridging to warfarin
• All others including history of HIT and malignancy → apixaban (Eliquis®) 10 mg PO BID x 7 days then 5 mg PO BID
• If a procedure is planned during the hospitalization and GFR is greater than or equal to 15, the use of enoxaparin over heparin gtt is preferred

Superficial Vein Thrombosis

Treat with Rivaroxaban (Xarelto®) 10 mg PO daily x 45 days IF:

Greater than or equal to 5 cm in length

OR

Less than or equal to 5 cm from a deep vein

AND no contraindications for blood thinning agents

Follow with primary care physician within one week

If neither of the above are met then symptomatic care only

Reference:

Beyer-Westendorf J, Schellong SM, Gerlack H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R. *“Prevention of thromboembolic complications in patients with superficial- vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-interfiority SUPRPRISE phase 3b trial”* Lancet Haematol. 2017; 4(3).